Please assess the completion status of the following clinical trial:

Trial Title: suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or above 18 years~* Male or female gender~* In case of women, unwillingness to remain pregnant during the study period.~* Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent~* Confirmed infection by SARS-CoV-2 virus using molecular techniques as defined by the World Health Organization~* Findings in chest-X-ray or in chest computed tomography compatible with lower respiratory tract infection~* Plasma suPAR ≥6ng/ml~Exclusion Criteria:~* Age below 18 years~* Denial for written informed consent~* Any stage IV malignancy~* Any do not resuscitate decision~* Any primary immunodeficiency~* Less than 1,500 neutrophils/mm3~* Known hypersensitivity to anakinra~* Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg prednisone for a greater period than the last 15 days.~* Any anti-cytokine biological treatment the last one month~* Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study~* Severe hepatic failure~* Severe renal failure~* Any need for CPAP or mechanical ventilation~* Any pO2/FiO2 ratio less than 150

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Patients will receive 100mg of anakinra subcutaneously once daily for ten days. The drugs should be administered on the same time ± 2 hours every day. All other administered drugs are allowed. In case the patient is discharged home before the completion of 10 days of treatment, it is at the discretion of the investigator to suggest treatment continuation at home. In case such a decision is taken, the patient will be provided the required number of pre-filled syringes for daily self-injection. In this case, the patient should return the empty used syringes within 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).